Cost analysis in favor of a combined approach for cytomegalovirus after kidney transplantation: A single-center experience

Transplant Infectious Disease

Volumn 15, Issue 1, 2013, Pages 70-78

  Hellemans, R ^a   Beutels, P ^b   Ieven, M ^a   Verpooten, G A ^a,b   Bosmans, J L ^a,b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Cost; Cytomegalovirus; Ganciclovir; Kidney transplant; Preemptive; Prophylaxis; Valganciclovir

Indexed keywords

ATG FRESENIUS S; BASILIXIMAB; CYCLOSPORIN; DACLIZUMAB; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST OF ILLNESS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG COST; ENTERITIS; FEMALE; GRAFT RECIPIENT; HEALTH CARE COST; HOSPITALIZATION COST; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LENGTH OF STAY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIVIRAL AGENTS; BELGIUM; COST-BENEFIT ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG COSTS; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; YOUNG ADULT;

EID: 84873435246     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12023     Document Type: Article

References (14)

1. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329-337.
2. Sagedal S, Nordal KP, Hartmann A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850-856.
3. Johnson PC, Lewis RM, Golden DL, et al. The impact of cytomegalovirus infection on seronegative recipients of seropositive donor kidneys versus seropositive recipients treated with cyclosporine-prednisone immunosuppression. Transplantation 1988; 45: 116-121.
4. Hodson EM, Craig JC, Strippoli GF, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008; April 16 (2): CD003774.
5. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian Society of Transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218-227.
6. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134-2143.
7. Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8: 69-77.
8. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8: 975-983.
9. Zhang LF, Wang YT, Tian JH, Yang KH, Wang JQ. Preemptive versus prophylactic protocol to prevent cytomegalovirus infection after renal transplantation: a meta-analysis and systematic review of randomized controlled trials. Transpl Infect Dis 2011; 13 (6): 622-632.
10. Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant 2008; 8: 2111-2118.
11. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228-1237.
12. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262-274.
13. Huisman M. Imputation of missing item responses: some simple techniques. Qual Quant 2000; 34: 331-351.
14. Dmitrienko S, Yu A, Balshaw R, Shapiro RJ, Keown PA. The use of consensus guidelines for management of cytomegalovirus infection in renal transplantation. Kidney Int 2007; 72: 1014-1022.